Monopar Therapeutics Inc. (MNPR)
NASDAQ · Manufacturing · Pharmaceutical preparations
MNPR price, last 12 months
Key stats
- Previous close
- $88.84
- Open
- $88.00
- Day range
- $85.06 – $90.00
- 52-week range
- $50.07 – $124.82
- Volume
- 83.3K
- Avg volume (20 days)
- 144.3K
- Market cap
- $572.1M
Performance
Technicals and fundamentals
About Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $572.1M